 |
|
|
| |
Efficacy and safety of DAA-based oral therapy in a large cohort of HCV patients
treated in clinical practice in Italy and monitored by the NAVIGATORE web-platform
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Marrtta Miillan1, PiierrGiirrogiio Scotttton3, Lucas G.. Cavallllarro2, Moniica Basso1 Sandrro Panese4, Diiego Tempestta4, Sarra Piiovesan1, Anna Marriia Cattttellan6, Daviide Campagnollo1, Pattrriiziia Burrrra5, Frrancesco P.. Russo5,
Anttoniio Carrllotttto11, Paollo Angellii7, Allessandrro Varriio8, Paollo Fabrriis9, Tosca Berrttiin9, Maurriiziio Carrrrarra10, Liilliiana Chemellllo7, Piierrangello Roverre12, Frranco Caprra13, Giiada Carrollo13, Sallvattorre Lobellllo14, Siillviia
Adamii15, Giiovanna Scrroccarro15, Alfredo Albertii1 on behalf of the NAVIIGATORE GROUP
1 DMM, University of Padova, 2 Ospedale Belluno, 3 Ospedale Treviso, 4 Ospedale Venezia-Mestre, 5 Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche (DiSCOG), University of Padova, 6 Azienda Ospedaliera di Padova, 7 Clinica Medica 5, University of Padova, 8 Ospedale
Schiavonia, 9 Ospedale Vicenza, 10 Ospedale Bussolengo, 11 Ospedale Santorso, 12 Ospedale Legnago, 13 University of Verona, 14 Ospedale S Antonio-Padova, 15 Regione Veneto-Venezia, ITALY.
HCC Risk/DAAs - Long Term Followup SVR / SVR Durability
AASLD: "Incidence and pattern of "de novo" hepatocellular carcinoma in HCV patients treated with oral DAAs" Navigatore Study Group- (11/17/16) this was an oral presentation, authors conclude: "the results of this ongoing prospective study indicate that cirrhotic patients with HCV treatment with DAAs are not at increased risk of developing HCC compared to untreated patients. Development of HCC during/after DAAs was associated with more advanced disease and with treatment failure. A subgroup of patients treated with DAAs developed a more aggressive type of HCC suggesting that immunological/molecular changes in the liver mircoenvironment, possibly induced by rapid suppression of HCV replication, might boost growth and spread of microscopic and therefore initially invisible HCC foci. further studies are needed to better clarify this observation and to identify prospective markers. HCV patients treated with DAAs with advanced liver disease should continue to be closely monitored for HCC"
|
| |
|
|
|
|
|
